*** Welcome to piglix ***

TAP Pharmaceuticals


TAP Pharmaceuticals was an American pharmaceutical company headquartered in Lake Forest, IL. It was a joint venture formed in 1977 between Abbott Laboratories and the Japanese pharmaceutical company Takeda. The joint venture was dissolved in 2008 and most of the company merged with Takeda.

TAP had several marketed products selling within the United States:

"Fourteen years ago, TAP had 200 employees. Today, the company has grown to more than 3,300 employees. As TAP evolves and grows to meet the needs of customers, the challenge will be to maintain the energy and optimism that makes TAP unique. Ultimately, it is not the size of the company that matters—TAP's success will be measured by how well the company meets the challenge of serving patients. TAP believes that the best way to meet that challenge is to live and work by its mission and the Spirit of TAP.

Throughout TAP's history, its efforts have been focused on developing and bringing innovative treatments to the people who need them. LUPRON INJECTION (leuprolide acetate), TAP's first product, was the first new hormonal therapy for the palliative treatment of advanced prostate cancer in 40 years. Prevacid (lansoprazole), a proton pump inhibitor (PPI), quickly became one of the most widely prescribed therapies for acid-related disease in North America. And the focus on innovation continues as the people of TAP work to improve patient convenience with new dosing and packaging advancements, research new indications for existing products, and develop new products in the pipeline."

Takeda Chemical Industries, Ltd. and Abbott form a joint research partnership, Takeda-Abbott Products (TAP).

LUPRON INJECTION (leuprolide acetate) approved by FDA for palliative treatment of advanced prostate cancer, the first new hormonal treatment for prostate cancer in 40 years.

Lupron Depot 7.5 mg approved for palliative treatment of advanced prostate cancer.

Lupron Depot 3.75 mg approved for management of endometriosis.

Lupron Depot-PED (leuprolide acetate for depot suspension) approved for treatment of central precocious puberty.

TAPCare introduced.

Prevacid approved by FDA for short-term treatment of erosive esophagitis, active duodenal ulcers and pathological hypersecretory conditions. Lupron Depot 3.75 approved, in combination with iron, for presurgical treatment of anemia caused by uterine fibroids. Lupron Depot-3 Month 22.5 mg approved for palliative treatment of advanced prostate cancer. CaPSURETM introduced.

Prevacid approved for long-term maintenance of healed erosive esophagitis.


...
Wikipedia

...